Preanalytical Stability of Flucloxacillin, Piperacillin, Tazobactam, Meropenem, Cefalexin, Cefazolin, and Ceftazidime in Therapeutic Drug Monitoring: A Structured Review.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
received:
22
10
2021
accepted:
22
01
2022
pubmed:
18
2
2022
medline:
16
11
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
Therapeutic drug monitoring is increasingly being used to optimize beta-lactam antibiotic dosing. Because beta-lactams are inherently unstable, confirming preanalytical sample stability is critical for reporting reliable results. This review aimed to summarize the published literature on the preanalytical stability of selected widely prescribed beta-lactams used in therapeutic drug monitoring. The published literature (2010-2020) on the preanalytical stability of flucloxacillin, piperacillin, tazobactam, meropenem, cefalexin, cefazolin, and ceftazidime in human plasma, serum, and whole blood was reviewed. Articles examining preanalytical stability at room temperature, refrigerated, or frozen (-20°C) using liquid chromatography with mass spectrometry or ultraviolet detection were included. Summarizing the available data allowed for general observations to be made, although data were conflicting in some cases (piperacillin, tazobactam, ceftazidime, and meropenem at room temperature, refrigerated, or -20°C) or limited (cefalexin, cefazolin, and flucloxacillin at -20°C). Overall, with the exception of the more stable cefazolin, preanalytical instability was observed after 6-12 hours at room temperature, 2-3 days when refrigerated, and 1-3 weeks when frozen at -20°C. In all cases, excellent stability was detected at -70°C. Studies focusing on preanalytical stability reported poorer stability than studies investigating stability as part of method validation. Based on this review, as general guidance, clinical samples for beta-lactam analysis should be refrigerated and analyzed within 2 days or frozen at -20°C and analyzed within 1 week. For longer storage times, freezing at -70°C was required to ensure sample stability. This review highlights the importance of conducting well-designed preanalytical stability studies on beta-lactams and other potentially unstable drugs under clinically relevant conditions.
Sections du résumé
BACKGROUND
Therapeutic drug monitoring is increasingly being used to optimize beta-lactam antibiotic dosing. Because beta-lactams are inherently unstable, confirming preanalytical sample stability is critical for reporting reliable results. This review aimed to summarize the published literature on the preanalytical stability of selected widely prescribed beta-lactams used in therapeutic drug monitoring.
METHODS
The published literature (2010-2020) on the preanalytical stability of flucloxacillin, piperacillin, tazobactam, meropenem, cefalexin, cefazolin, and ceftazidime in human plasma, serum, and whole blood was reviewed. Articles examining preanalytical stability at room temperature, refrigerated, or frozen (-20°C) using liquid chromatography with mass spectrometry or ultraviolet detection were included.
RESULTS
Summarizing the available data allowed for general observations to be made, although data were conflicting in some cases (piperacillin, tazobactam, ceftazidime, and meropenem at room temperature, refrigerated, or -20°C) or limited (cefalexin, cefazolin, and flucloxacillin at -20°C). Overall, with the exception of the more stable cefazolin, preanalytical instability was observed after 6-12 hours at room temperature, 2-3 days when refrigerated, and 1-3 weeks when frozen at -20°C. In all cases, excellent stability was detected at -70°C. Studies focusing on preanalytical stability reported poorer stability than studies investigating stability as part of method validation.
CONCLUSIONS
Based on this review, as general guidance, clinical samples for beta-lactam analysis should be refrigerated and analyzed within 2 days or frozen at -20°C and analyzed within 1 week. For longer storage times, freezing at -70°C was required to ensure sample stability. This review highlights the importance of conducting well-designed preanalytical stability studies on beta-lactams and other potentially unstable drugs under clinically relevant conditions.
Identifiants
pubmed: 35175248
doi: 10.1097/FTD.0000000000000975
pii: 00007691-202212000-00001
doi:
Substances chimiques
Meropenem
FV9J3JU8B1
Piperacillin
X00B0D5O0E
Ceftazidime
9M416Z9QNR
Tazobactam
SE10G96M8W
Floxacillin
43B2M34G2V
Cefazolin
IHS69L0Y4T
Cephalexin
OBN7UDS42Y
Anti-Bacterial Agents
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
709-719Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Parker SL, Sime FB, Roberts JA. Optimizing dosing of antibiotics in critically ill patients. Curr Opin Infect Dis. 2015;28:497–504.
Carlier M, Carrette S, Stove V, et al. Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course. Int J Antimicrob Agents. 2014;43:470–473.
Sime FB, Roberts MS, Peake SL, et al. Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care. 2012;2:35.
Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840–851.
Carlier M, Stove V, Wallis SC, et al. Assays for therapeutic drug monitoring of beta-lactam antibiotics: a structured review. Int J Antimicrob Agents. 2015;46:367–375.
Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46:1127–1153.
Deshpande AD. Degradation β-lactam antibiotics. Curr Sci. 2004;87:1684–1695.
Kipper K, Barker CIS, Standing JF, et al. Development of a novel multipenicillin assay and assessment of the impact of analyte degradation: lessons for scavenged sampling in antimicrobial pharmacokinetic study design. Antimicrob Agents Chemother. 2018;62:100.
Pinder N, Brenner T, Swoboda S, et al. Therapeutic drug monitoring of beta-lactam antibiotics - influence of sample stability on the analysis of piperacillin, meropenem, ceftazidime and flucloxacillin by HPLC-UV. J Pharm Biomed. 2017;143:86–93.
Rigo-Bonnin R, Ribera A, Arbiol-Roca A, et al. Development and validation of a measurement procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry for simultaneous measurement of beta-lactam antibiotic concentration in human plasma. Clin Chim Acta. 2017;468:215–224.
Zander J, Maier B, Zoller M, et al. Effects of biobanking conditions on six antibiotic substances in human serum assessed by a novel evaluation protocol. Clin Chem Lab. 2016;54:265–274.
EMEA. European Medicines Agency: Guideline on Bioanalytic Method Validation. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf . Accessed September 5, 2021.
FDA. Guidance for Industry: Bioanalytic Method Validation. Available at: https://www.fda.gov/downloads/drugs/guidances/ucm070107.Pdf . Accessed September 5, 2021.
Ahsman MJ, Wildschut ED, Tibboel D, et al. Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates. Antimicrob Agents Chemother. 2009;53:75–80.
Denooz R, Charlier C. Simultaneous determination of five beta-lactam antibiotics (cefepim, ceftazidim, cefuroxim, meropenem and piperacillin) in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B. 2008;864:161–167.
Isla A, Arzuaga A, Maynar J, et al. Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC. J Pharm Biomed. 2005;39:996–1005.
Decosterd LA, Mercier T, Ternon B, et al. Validation and clinical application of a multiplex high performance liquid chromatography-tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections. J Chromatogr B. 2020;1157:122160.
Barco S, Mesini A, Barbagallo L, et al. A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: application to critically ill pediatric patients. J Pharm Biomed. 2020;186:113273.
Mortensen JS, Jensen BP, Zhang M, et al. Preanalytical stability of piperacillin, tazobactam, meropenem, and ceftazidime in plasma and whole blood using liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2019;41:538–543.
D'Cunha R, Bach T, Young BA, et al. Quantification of cefepime, meropenem, piperacillin, and tazobactam in human plasma using a sensitive and robust liquid chromatography-tandem mass spectrometry method, part 2: stability evaluation. Antimicrob Agents Chemother. 2018;62:e00861–e00818.
Girdwood SC, Tang PH, Murphy ME, et al. Demonstrating feasibility of an opportunistic sampling approach for pharmacokinetic studies of β-lactam antibiotics in critically ill children. J Clin Pharmacol. 2020;61:565–573.
Carlier M, De Waele JJ, Verstraete AG, et al. Exploration of the pre-analytical stability of beta-lactam antibiotics in plasma and blood-implications for therapeutic drug monitoring and pharmacokinetic studies. Clin Chem Lab. 2015;53:e227–e230.
do Nascimento TG, de Jesus Oliveira E, Basilio Junior ID, et al. Short-term stability studies of ampicillin and cephalexin in aqueous solution and human plasma: application of least squares method in Arrhenius equation. J Pharm Biomed. 2013;73:59–64.
Martens-Lobenhoffer J, Monastyrski D, Tröger U, et al. Stability of meropenem in plasma versus dried blood spots (DBS). J Pharm Biomed. 2019;170:279–284.
Martens-Lobenhoffer J, Bode-Boger SM. Quantification of meropenem in human plasma by HILIC-tandem mass spectrometry. J Chromatogr B. 2017;1046:13–17.
Lefeuvre S, Bois-Maublanc J, Hocqueloux L, et al. A simple ultra-high-performance liquid chromatography-high resolution mass spectrometry assay for the simultaneous quantification of 15 antibiotics in plasma. J Chromatogr B. 2017;1065:50–58.
El-Najjar N, Hosl J, Holzmann T, et al. UPLC-MS/MS method for therapeutic drug monitoring of 10 antibiotics used in intensive care units. Drug Test Anal. 2018;10:584–591.
Sime FB, Roberts MS, Roberts JA, et al. Simultaneous determination of seven beta-lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokinetic studies. J Chromatogr B. 2014;960:134–144.
Huang C, Gao J, Miao L. Simultaneous determination of flucloxacillin and ampicillin in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and subsequent application to a clinical study in healthy Chinese volunteers. J Pharm Biomed. 2012;59:157–161.
Chahbouni A, den Dungen FA, Vos RM, et al. An UPLC-MS detection method for the quantification of five antibiotics in human plasma. Bioanalysis. 2015;7:2321–2329.
Rehm S, Rentsch KM. A 2D HPLC-MS/MS method for several antibiotics in blood plasma, plasma water, and diverse tissue samples. Anal Bioanal Chem. 2020;412:715–725.
Barco S, Bandettini R, Maffia A, et al. Quantification of piperacillin, tazobactam, meropenem, ceftazidime, and linezolid in human plasma by liquid chromatography/tandem mass spectrometry. J Chemother 2015;27:343–347.
Chen F, Hu ZY, Laizure SC, et al. Simultaneous assay of multiple antibiotics in human plasma by LC-MS/MS: importance of optimizing formic acid concentration. Bioanalysis. 2017;9:469–483.
Cohen-Wolkowiez M, White NR, Bridges A, et al. Development of a liquid chromatography-tandem mass spectrometry assay of six antimicrobials in plasma for pharmacokinetic studies in premature infants. J Chromatogr B. 2011;879:3497–3506.
Ferrone V, Cotellese R, Carlucci M, et al. Air assisted dispersive liquid-liquid microextraction with solidification of the floating organic droplets (AA-DLLME-SFO) and UHPLC-PDA method: application to antibiotics analysis in human plasma of hospital acquired pneumonia patients. J Pharm Biomed. 2018;151:266–273.
Legrand T, Vodovar D, Tournier N, et al. Simultaneous determination of eight beta-lactam antibiotics, amoxicillin, cefazolin, cefepime, cefotaxime, ceftazidime, cloxacillin, oxacillin, and piperacillin in human plasma by using ultra-high-performance liquid chromatography with ultraviolet detection. Antimicrob Agents Chemother. 2016;60:4734–4742.
Naicker S, Valero YC, Meija JL, et al. A UHPLC-MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. J Pharm Biomed. 2018;148:324–333.
Paal M, Zoller M, Schuster C, et al. Simultaneous quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid and piperacillin in human serum using an isotope-dilution HPLC-MS/MS method. J Pharm Biomed. 2018;152:102–110.
Popowicz ND, O'Halloran SJ, Fitzgerald D, et al. A rapid, LC-MS/MS assay for quantification of piperacillin and tazobactam in human plasma and pleural fluid: application to a clinical pharmacokinetic study. J Chromatogr B. 2018;1081:58–66.
Zander J, Maier B, Suhr A, et al. Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation. Clin Chem Lab. 2015;53:781–791.
Milla P, Ferrari F, Muntoni E, et al. Validation of a simple and economic HPLC-UV method for the simultaneous determination of vancomycin, meropenem, piperacillin and tazobactam in plasma samples. J Chromatogr B. 2020;1148:122151.
Ferrari D, Ripa M, Premaschi S, et al. LC-MS/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples. J Pharm Biomed. 2019;169:11–18.
Sutherland CA, Nicolau DP. Development of an HPLC method for the determination of ceftolozane/tazobactam in biological and aqueous matrixes. J Chromatogr Sci. 2016;54:1037–1040.
Ezquer-Garin C, Ferriols-Lisart R, Alos-Alminana M, et al. Validated HPLC-UV detection method for the simultaneous determination of ceftolozane and tazobactam in human plasma. Bioanalysis. 2018;10:461–473.
Rigo-Bonnin R, Gomez-Junyent J, Garcia-Tejada L, et al. Measurement of ceftolozane and tazobactam concentrations in plasma by UHPLC-MS/MS: clinical application in the management of difficult-to-treat osteoarticular infections. Clin Chim Acta. 2019;488:50–60.
Putnam WC, Kallem RR, Edpuganti V, et al. Development and validation of a quantitative LC-MS/MS method for the simultaneous determination of ceftolozane and tazobactam in human plasma and urine. J Chromatogr B. 2020;1159:122354.
Cardoso CR, Alves MIR, Antoniosi Filho NR. Determination of amoxicillin in human plasma using cephalexin as an internal standard and HPLC-MS/MS for the application of bioquivalence studies. Int Res J Pharm. 2012;2:299–305.
Zhang M, Moore GA, Chin PK, et al. Simultaneous determination of cefalexin, cefazolin, flucloxacillin and probenecid by liquid chromatography-tandem mass spectrometry for total and unbound concentrations in human plasma. Ther Drug Monit. 2018;40:682–692.
Crutchfield CA, Marzinke MA. Bioanalytical development and validation of liquid chromatographic-tandem mass spectrometric methods for the quantification of total and free cefazolin in human plasma and cord blood. Pract Lab Med. 2015;1:12–21.
Kiriazopoulos E, Zaharaki S, Vonaparti A, et al. Quantification of three beta-lactam antibiotics in breast milk and human plasma by hydrophilic interaction liquid chromatography/positive-ion electrospray ionization mass spectrometry. Drug Test Anal. 2017;9:1062–1072.
Kunicki PK, Waś J. Simple HPLC method for cefazolin determination in human serum – validation and stability testing. J Chromatogr B Biomed Appl. 2012;911:133–139.
Rehm S, Rentsch KM. LC-MS/MS method for nine different antibiotics. Clin Chim Acta. 2020;511:360–367.
Rigo-Bonnin R, Cobo-Sacristan S, Padulles A, et al. Measurement of ceftazidime concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry: application to critically ill patients and patients with osteoarticular infections. Biomed Chromatogr. 2016;30:410–418.
Sillen H, Mitchell R, Sleigh R, et al. Determination of avibactam and ceftazidime in human plasma samples by LC-MS. Bioanalysis. 2015;7:1423–1434.
Dailly E, Bouquie R, Deslandes G, et al. A liquid chromatography assay for a quantification of doripenem, ertapenem, imipenem, meropenem concentrations in human plasma: application to a clinical pharmacokinetic study. J Chromatogr B. 2011;879:1137–1142.
Rigo-Bonnin R, Juvany-Roig R, Leiva-Badosa E, et al. Measurement of meropenem concentration in different human biological fluids by ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2014;406:4997–5007.
Rehm S, Rentsch KM. HILIC LC-MS/MS method for the quantification of cefepime, imipenem and meropenem. J Pharm Biomed. 2020;186:113289.
Kammoun AK, Khedr A, Khayyat AN, et al. Ultra-performance liquid chromatography-tandem mass spectrometric method for quantitation of the recently Food and Drug Administration approved combination of vaborbactam and meropenem in human plasma. R Soc Open Sci. 2020;7:200635.
Zou L, Meng F, Hu L, et al. A novel reversed-phase high-performance liquid chromatographic assay for the simultaneous determination of imipenem and meropenem in human plasma and its application in TDM. J Pharm Biomed. 2019;169:142–150.
Dincel D, Sagirli O, Topcu G. A high-performance liquid chromatographic method for the determination of meropenem in serum. J Chromatogr Sci. 2019;58:144–150.
Carlier M, Athanasopoulos A, Borrey D, et al. Proficiency testing for meropenem and piperacillin therapeutic drug monitoring: preliminary results from the Belgian Society on Infectiology and Clinical Microbiology Pharmacokinetic-Pharmacodynamic Working Group. Ther Drug Monit. 2018;40:156–158.
Wallenburg E, Brüggemann RJ, Asouit K, et al. First international quality control programme for laboratories measuring antimicrobial drugs to support dose individualization in critically ill patients. J Antimicrob Chemother. 2020;76:430–433.